- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT01386385
Велипариб с лучевой терапией или без нее, карбоплатином и паклитакселом у пациентов с немелкоклеточным раком легкого III стадии, который не может быть удален хирургическим путем
Исследование по определению дозы, за которым последовало рандомизированное плацебо-контролируемое исследование фазы II велипариба (ABT-888), добавленного к химиолучевой терапии с карбоплатином и паклитакселом для лечения неоперабельного немелкоклеточного рака легкого III стадии (НМРЛ), (исследование NCI № 8811)
This phase I/II partially randomized trial studies the side effects and best dose of veliparib when given together with radiation therapy, carboplatin, and paclitaxel and to see how well it works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether radiation therapy, carboplatin, and paclitaxel are more effective with or without veliparib in treating non-small cell lung cancer.
Обзор исследования
Статус
Условия
- Аденокарцинома легкого
- Крупноклеточная карцинома легкого
- Стадия IIIA немелкоклеточного рака легкого AJCC v7
- Минимально инвазивная аденокарцинома легкого
- Стадия IIIB немелкоклеточного рака легкого AJCC v7
- Немелкоклеточный рак легкого III стадии AJCC v7
- Плоскоклеточный рак легкого
- Аденокарцинома легкого, смешанный подтип
Подробное описание
PRIMARY OBJECTIVES:
I. To establish the maximum tolerated dose (MTD) and the recommended phase II dose of ABT-888 (veliparib) when given concurrently with standard carboplatin/paclitaxel and radiotherapy in patients with unresectable stage III non-small cell lung cancer (NSCLC). (Phase I) II. To assess whether carboplatin/paclitaxel plus ABT-888 compared with carboplatin/paclitaxel plus placebo improves progression-free survival (PFS) in patients with unresectable stage III NSCLC. (Phase II) III. To compare overall survival (OS) in patients treated with carboplatin/paclitaxel and radiotherapy plus ABT-888 to those treated with carboplatin, paclitaxel and radiotherapy plus placebo. (Phase II) IV. To assess the response rate (confirmed and unconfirmed, complete and partial responses) and disease control rate in the subset of patients with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. (Phase II) V. To assess the safety and toxicity profile of the regimen. (Phase II)
SECONDARY OBJECTIVES:
I. To collect tumor tissue from pretreatment biopsies (archival samples) for biomarker studies, including poly (ADP-ribose) polymerase 1 (PARP) activity by measuring the levels of poly-ADP-ribose, gamma-H2A histone family, member X (gamma-H2AX), and messenger ribonucleic acid (mRNA) expression levels of deoxyribonucleic acid (DNA) repair enzymes such as excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1)/x-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1).
II. To collect blood samples for evaluation of gamma-H2AX (circulating tumor cells) and other relevant future studies.
OUTLINE: This is a phase I, dose-escalation study of veliparib followed by a randomized phase II study.
PHASE I:
INDUCTION THERAPY: Patients undergo 3-dimensional conformal radiation therapy (3D-CRT) once daily (QD), 5 days a week, for 6 weeks. Patients also receive veliparib orally (PO) twice daily (BID) on days 1-43 and carboplatin intravenously (IV) over 30 minutes and paclitaxel IV over 1 hour on days 1, 8, 15, 22, 36, and 43 in the absence of disease progression or unacceptable toxicity. Patients without disease progression after completion of chemoradiotherapy undergo consolidation therapy.
CONSOLIDATION THERAPY: Beginning within 4-6 weeks of chemotherapy and radiation therapy, patients receive veliparib PO BID on days 1-7 (course 1) and 22-28 (course 2) and carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1 and on day 22 of course 2. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
PHASE II: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo 3D-CRT and receive veliparib, carboplatin, and paclitaxel as in Phase I induction and consolidation therapy.
ARM II: Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days 1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of chemotherapy and radiation therapy, patients receive placebo on days 1-7 and carboplatin and paclitaxel as in Phase I.
After completion of study treatment, patients are followed up every 4 months for first 2 years and then every 6 months until 5 years.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
Alaska
-
Anchorage, Alaska, Соединенные Штаты, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Tucson, Arizona, Соединенные Штаты, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Соединенные Штаты, 85719
- University of Arizona Cancer Center-North Campus
-
-
California
-
Beverly Hills, California, Соединенные Штаты, 90211
- Tower Cancer Research Foundation
-
Burbank, California, Соединенные Штаты, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Corona, California, Соединенные Штаты, 92882
- City of Hope Corona
-
Duarte, California, Соединенные Штаты, 91010
- City of Hope Comprehensive Cancer Center
-
Los Angeles, California, Соединенные Штаты, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Соединенные Штаты, 90033
- Los Angeles General Medical Center
-
Merced, California, Соединенные Штаты, 95340
- Mercy Cancer Center
-
Sacramento, California, Соединенные Штаты, 95817
- University of California Davis Comprehensive Cancer Center
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- UCHealth University of Colorado Hospital
-
-
Connecticut
-
New Haven, Connecticut, Соединенные Штаты, 06520
- Yale University
-
-
Hawaii
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Соединенные Штаты, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Соединенные Штаты, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Соединенные Штаты, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Соединенные Штаты, 96826
- Kapiolani Medical Center for Women and Children
-
Lihue, Hawaii, Соединенные Штаты, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Соединенные Штаты, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Соединенные Штаты, 96701
- Queen's Cancer Center - Pearlridge
-
‘Aiea, Hawaii, Соединенные Штаты, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Idaho
-
Boise, Idaho, Соединенные Штаты, 83712
- Saint Luke's Cancer Institute - Boise
-
Coeur d'Alene, Idaho, Соединенные Штаты, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Соединенные Штаты, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Соединенные Штаты, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Соединенные Штаты, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Соединенные Штаты, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Соединенные Штаты, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Соединенные Штаты, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Aurora, Illinois, Соединенные Штаты, 60504
- Rush-Copley Medical Center
-
Bloomington, Illinois, Соединенные Штаты, 61704
- Illinois CancerCare-Bloomington
-
Bloomington, Illinois, Соединенные Штаты, 61701
- OSF Saint Joseph Medical Center
-
Canton, Illinois, Соединенные Штаты, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Соединенные Штаты, 62902
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Соединенные Штаты, 62918
- SIH Cancer Institute
-
Carthage, Illinois, Соединенные Штаты, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Соединенные Штаты, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Соединенные Штаты, 60611
- Northwestern University
-
Danville, Illinois, Соединенные Штаты, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Соединенные Штаты, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Соединенные Штаты, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Соединенные Штаты, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Соединенные Штаты, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Соединенные Штаты, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Соединенные Штаты, 61401
- Illinois CancerCare-Galesburg
-
Kewanee, Illinois, Соединенные Штаты, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Соединенные Штаты, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Соединенные Штаты, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Соединенные Штаты, 60153
- Loyola University Medical Center
-
Mount Vernon, Illinois, Соединенные Штаты, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Соединенные Штаты, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Соединенные Штаты, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Соединенные Штаты, 61554
- Illinois CancerCare-Pekin
-
Pekin, Illinois, Соединенные Штаты, 61554
- OSF Saint Francis Radiation Oncology at Pekin
-
Peoria, Illinois, Соединенные Штаты, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Соединенные Штаты, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Соединенные Штаты, 61615
- Illinois CancerCare-Peoria
-
Peoria, Illinois, Соединенные Штаты, 61615
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center
-
Peru, Illinois, Соединенные Штаты, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Соединенные Штаты, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Соединенные Штаты, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Соединенные Штаты, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Соединенные Штаты, 62702
- Springfield Clinic
-
Springfield, Illinois, Соединенные Штаты, 62702
- Central Illinois Hematology Oncology Center
-
Springfield, Illinois, Соединенные Штаты, 62781
- Springfield Memorial Hospital
-
Swansea, Illinois, Соединенные Штаты, 62226
- Southwest Illinois Health Services LLP
-
Urbana, Illinois, Соединенные Штаты, 61801
- Carle Cancer Center
-
Urbana, Illinois, Соединенные Штаты, 61801
- The Carle Foundation Hospital
-
Yorkville, Illinois, Соединенные Штаты, 60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Fort Wayne, Indiana, Соединенные Штаты, 46845
- Fort Wayne Medical Oncology and Hematology Inc-Parkview
-
Richmond, Indiana, Соединенные Штаты, 47374
- Reid Health
-
-
Iowa
-
Ames, Iowa, Соединенные Штаты, 50010
- McFarland Clinic - Ames
-
Sioux City, Iowa, Соединенные Штаты, 51101
- Siouxland Regional Cancer Center
-
-
Kansas
-
Chanute, Kansas, Соединенные Штаты, 66720
- Cancer Center of Kansas - Chanute
-
Dodge City, Kansas, Соединенные Штаты, 67801
- Cancer Center of Kansas - Dodge City
-
El Dorado, Kansas, Соединенные Штаты, 67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott, Kansas, Соединенные Штаты, 66701
- Cancer Center of Kansas - Fort Scott
-
Garden City, Kansas, Соединенные Штаты, 67846
- Saint Catherine Hospital
-
Great Bend, Kansas, Соединенные Штаты, 67530
- Central Care Cancer Center - Great Bend
-
Hays, Kansas, Соединенные Штаты, 67601
- HaysMed
-
Independence, Kansas, Соединенные Штаты, 67301
- Cancer Center of Kansas-Independence
-
Kansas City, Kansas, Соединенные Штаты, 66160
- University of Kansas Cancer Center
-
Kansas City, Kansas, Соединенные Штаты, 66112
- University of Kansas Cancer Center-West
-
Kingman, Kansas, Соединенные Штаты, 67068
- Cancer Center of Kansas-Kingman
-
Lawrence, Kansas, Соединенные Штаты, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Соединенные Штаты, 67905
- Cancer Center of Kansas-Liberal
-
Manhattan, Kansas, Соединенные Штаты, 66502
- Cancer Center of Kansas-Manhattan
-
McPherson, Kansas, Соединенные Штаты, 67460
- Cancer Center of Kansas - McPherson
-
Newton, Kansas, Соединенные Штаты, 67114
- Cancer Center of Kansas - Newton
-
Olathe, Kansas, Соединенные Штаты, 66061
- The University of Kansas Cancer Center - Olathe
-
Overland Park, Kansas, Соединенные Штаты, 66210
- University of Kansas Cancer Center-Overland Park
-
Parsons, Kansas, Соединенные Штаты, 67357
- Cancer Center of Kansas - Parsons
-
Pittsburg, Kansas, Соединенные Штаты, 66762
- Mercy Hospital Pittsburg
-
Pratt, Kansas, Соединенные Штаты, 67124
- Cancer Center of Kansas - Pratt
-
Salina, Kansas, Соединенные Штаты, 67401
- Salina Regional Health Center
-
Salina, Kansas, Соединенные Штаты, 67401
- Cancer Center of Kansas - Salina
-
Topeka, Kansas, Соединенные Штаты, 66606
- University of Kansas Health System Saint Francis Campus
-
Wellington, Kansas, Соединенные Штаты, 67152
- Cancer Center of Kansas - Wellington
-
Westwood, Kansas, Соединенные Штаты, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
Wichita, Kansas, Соединенные Штаты, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, Соединенные Штаты, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Соединенные Штаты, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, Соединенные Штаты, 67208
- Associates In Womens Health
-
Wichita, Kansas, Соединенные Штаты, 67214
- Wesley Medical Center
-
Winfield, Kansas, Соединенные Штаты, 67156
- Cancer Center of Kansas - Winfield
-
-
Massachusetts
-
Burlington, Massachusetts, Соединенные Штаты, 01805
- Lahey Clinic
-
-
Michigan
-
Battle Creek, Michigan, Соединенные Штаты, 49017
- Bronson Battle Creek
-
Detroit, Michigan, Соединенные Штаты, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Соединенные Штаты, 48201
- Wayne State University/Karmanos Cancer Institute
-
Grand Rapids, Michigan, Соединенные Штаты, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Соединенные Штаты, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Соединенные Штаты, 49007
- West Michigan Cancer Center
-
Muskegon, Michigan, Соединенные Штаты, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Соединенные Штаты, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Reed City, Michigan, Соединенные Штаты, 49677
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Соединенные Штаты, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Соединенные Штаты, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, Соединенные Штаты, 49684
- Munson Medical Center
-
Wyoming, Michigan, Соединенные Штаты, 49519
- University of Michigan Health - West
-
-
Minnesota
-
Bemidji, Minnesota, Соединенные Штаты, 56601
- Sanford Joe Lueken Cancer Center
-
-
Mississippi
-
Southhaven, Mississippi, Соединенные Штаты, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Ballwin, Missouri, Соединенные Штаты, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bonne Terre, Missouri, Соединенные Штаты, 63628
- Parkland Health Center-Bonne Terre
-
Cape Girardeau, Missouri, Соединенные Штаты, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Соединенные Штаты, 63703
- Mercy Cancer Center - Cape Girardeau
-
Jefferson City, Missouri, Соединенные Штаты, 65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Соединенные Штаты, 64804
- Freeman Health System
-
Joplin, Missouri, Соединенные Штаты, 64804
- Mercy Hospital Joplin
-
Kansas City, Missouri, Соединенные Штаты, 64128
- Kansas City Veterans Affairs Medical Center
-
Kansas City, Missouri, Соединенные Штаты, 64154
- University of Kansas Cancer Center - North
-
Kansas City, Missouri, Соединенные Штаты, 64131
- The University of Kansas Cancer Center-South
-
Kansas City, Missouri, Соединенные Штаты, 64108
- University Health Truman Medical Center
-
Lee's Summit, Missouri, Соединенные Штаты, 64064
- University of Kansas Cancer Center - Lee's Summit
-
Rolla, Missouri, Соединенные Штаты, 65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve, Missouri, Соединенные Штаты, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Соединенные Штаты, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Соединенные Штаты, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Соединенные Штаты, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Соединенные Штаты, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Соединенные Штаты, 63141
- Mercy Hospital Saint Louis
-
Sullivan, Missouri, Соединенные Штаты, 63080
- Missouri Baptist Sullivan Hospital
-
Washington, Missouri, Соединенные Штаты, 63090
- Mercy Hospital Washington
-
-
Montana
-
Anaconda, Montana, Соединенные Штаты, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Соединенные Штаты, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Соединенные Штаты, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Соединенные Штаты, 59405
- Great Falls Clinic
-
Great Falls, Montana, Соединенные Штаты, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Соединенные Штаты, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Соединенные Штаты, 59901
- Logan Health Medical Center
-
Missoula, Montana, Соединенные Штаты, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Соединенные Штаты, 59804
- Community Medical Center
-
-
North Carolina
-
Hendersonville, North Carolina, Соединенные Штаты, 28791
- Margaret R Pardee Memorial Hospital
-
Kinston, North Carolina, Соединенные Штаты, 28501
- ECU Health Oncology Kinston
-
Pinehurst, North Carolina, Соединенные Штаты, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
-
North Dakota
-
Bismarck, North Dakota, Соединенные Штаты, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Соединенные Штаты, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Соединенные Штаты, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Canton, Ohio, Соединенные Штаты, 44708
- Cleveland Clinic Mercy Hospital
-
Centerville, Ohio, Соединенные Штаты, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Соединенные Штаты, 45459
- Dayton Physicians LLC-Miami Valley South
-
Cincinnati, Ohio, Соединенные Штаты, 45236
- Oncology Hematology Care Inc-Kenwood
-
Dayton, Ohio, Соединенные Штаты, 45406
- Good Samaritan Hospital - Dayton
-
Dayton, Ohio, Соединенные Штаты, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Соединенные Штаты, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Соединенные Штаты, 45415
- Dayton Physician LLC - Englewood
-
Findlay, Ohio, Соединенные Штаты, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, Соединенные Штаты, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, Соединенные Штаты, 45840
- Orion Cancer Care
-
Franklin, Ohio, Соединенные Штаты, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, Соединенные Штаты, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Соединенные Штаты, 45331
- Wayne Hospital
-
Greenville, Ohio, Соединенные Штаты, 45331
- Dayton Physicians LLC-Wayne
-
Kettering, Ohio, Соединенные Штаты, 45429
- Kettering Medical Center
-
Kettering, Ohio, Соединенные Штаты, 45409
- Greater Dayton Cancer Center
-
Middletown, Ohio, Соединенные Штаты, 45042
- Dayton Physicians LLC-Signal Point
-
Sidney, Ohio, Соединенные Штаты, 45365
- Dayton Physicians LLC-Wilson
-
Springfield, Ohio, Соединенные Штаты, 45504
- Springfield Regional Cancer Center
-
Springfield, Ohio, Соединенные Штаты, 45504
- Springfield Regional Medical Center
-
Troy, Ohio, Соединенные Штаты, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Соединенные Штаты, 45373
- Dayton Physicians LLC - Troy
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Bend, Oregon, Соединенные Штаты, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Соединенные Штаты, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Соединенные Штаты, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Соединенные Штаты, 97420
- Bay Area Hospital
-
Newberg, Oregon, Соединенные Штаты, 97132
- Providence Newberg Medical Center
-
Oregon City, Oregon, Соединенные Штаты, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Соединенные Штаты, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Соединенные Штаты, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Reading, Pennsylvania, Соединенные Штаты, 19605
- Penn State Health Saint Joseph Medical Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Соединенные Штаты, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Соединенные Штаты, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Collierville, Tennessee, Соединенные Штаты, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Memphis, Tennessee, Соединенные Штаты, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Houston, Texas, Соединенные Штаты, 77030
- UT MD Anderson Cancer Center
-
San Antonio, Texas, Соединенные Штаты, 78229
- University Hospital
-
San Antonio, Texas, Соединенные Штаты, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Соединенные Штаты, 78229
- Audie L Murphy VA Hospital
-
-
Washington
-
Aberdeen, Washington, Соединенные Штаты, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham, Washington, Соединенные Штаты, 98225
- PeaceHealth Saint Joseph Medical Center
-
Centralia, Washington, Соединенные Штаты, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Соединенные Штаты, 98026
- Swedish Cancer Institute-Edmonds
-
Everett, Washington, Соединенные Штаты, 98201
- Providence Regional Cancer Partnership
-
Issaquah, Washington, Соединенные Штаты, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Соединенные Штаты, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Соединенные Штаты, 98503
- Providence Regional Cancer System-Lacey
-
Longview, Washington, Соединенные Штаты, 98632
- PeaceHealth Saint John Medical Center
-
Seattle, Washington, Соединенные Штаты, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Соединенные Штаты, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Соединенные Штаты, 98112
- Kaiser Permanente Washington
-
Seattle, Washington, Соединенные Штаты, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Соединенные Штаты, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Shelton, Washington, Соединенные Штаты, 98584
- Providence Regional Cancer System-Shelton
-
Spokane, Washington, Соединенные Штаты, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane, Washington, Соединенные Штаты, 99218
- MultiCare Deaconess Cancer and Blood Specialty Center - North
-
Spokane Valley, Washington, Соединенные Штаты, 99216
- MultiCare Deaconess Cancer and Blood Specialty Center - Valley
-
Vancouver, Washington, Соединенные Штаты, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Соединенные Штаты, 99362
- Providence Saint Mary Regional Cancer Center
-
Yelm, Washington, Соединенные Штаты, 98597
- Providence Regional Cancer System-Yelm
-
-
Wyoming
-
Cody, Wyoming, Соединенные Штаты, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Соединенные Штаты, 82801
- Welch Cancer Center
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Patients must have histologically or cytologically-proven new diagnosis of unresectable stage IIIA/IIIB*, non-small cell lung cancer (adenocarcinoma, bronchioloalveolar cell carcinoma, large cell carcinoma, squamous cell carcinoma, or mixed)
- Per the American Joint Committee on Cancer (AJCC) 7th edition, pleural and pericardial are now considered stage M1a disease; when pleural fluid is visible on the computed tomography (CT) scan or on a chest x-ray, a thoracentesis is required to confirm that the pleural fluid is cytologically negative; patients with exudative pleural effusions are excluded, regardless of cytology; patients with effusions that are minimal (i.e. not visible on chest x-ray) that are too small to safely tap are eligible; a small effusion that has positive fludeoxyglucose F 18 (FDG) uptake on positron emission tomography (PET) has to be proven to be malignant per standard of care diagnostic procedures for the patient to be excluded
-
Patients must have measurable or non-measurable disease documented by CT, magnetic resonance imaging (MRI) or PET/CT; the CT from a combined PET/CT may be used to document only non-measurable disease unless the scan is of diagnostic quality; measurable disease must be assessed by CT within 28 days prior to registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form
-
Patients with brain metastases are ineligible; all patients must have a pretreatment CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to registration
-
Patients must not have received any prior systemic therapy (chemotherapy or other biologic therapy) for lung cancer
-
Patients must not have received prior chest radiation therapy for NSCLC
-
Patients must not have had a previous surgical resection; however, patients may have undergone exploratory thoracotomy, mediastinoscopy, excisional biopsy or similar surgery for the purpose of determining the diagnosis, stage or potential resectability of newly diagnosed lung tumor; at least 28 days must have elapsed since thoracic surgery (excluding mediastinoscopy or other minor surgeries) and patients should have recovered from all associated toxicities at the time of registration; patients must not be planning to undergo a minor surgical procedure while on this study
-
Patients must have Zubrod performance status 0-1
-
Patients must have tumor tissue available for submission to assess gene expression of ERCC1 and XRCC1; patients must also be offered participation in banking for future use of specimens
-
Absolute neutrophil count >= 1,500/mcl
-
Platelets >= 100,000/mcl
-
Hemoglobin >= 9.0 g/dl
-
Total bilirubin within institutional upper limit of normal (IULN)
-
Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x IULN
-
Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
-
Patients must have a serum creatinine =< the IULN AND measured or calculated creatinine clearance >= 60 cc/min using the Cockroft-Gault formula
-
Patients must have pulmonary function tests (PFTs) including forced expiratory volume in 1 second (FEV1) within 84 days prior to registration; for FEV1, the best value obtained pre- or post-bronchodilator must be >= 1.2 liters/second and/or >= 50% predicted
-
Patients may not be planning to receive any other investigational agents
-
Patients must not have more than 10% weight loss in the past 6 months
-
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888, carboplatin, paclitaxel or other agents used in study
-
No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years
-
Patient must not have any uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Patients must not currently have a > grade 1 symptomatic neuropathy-sensory (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4.0)
-
Patients must not have a history of seizures
-
Patients must not have any known immune deficiencies; patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; therefore, known human immunodeficiency virus (HIV) positive patients receiving combination anti-retroviral therapy are excluded from the study
-
Patients must be able to swallow whole capsules
-
Prestudy history and physical must be obtained within 28 days prior to registration
-
All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
-
As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY:
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have completed chemoradiotherapy per protocol and at least four weeks but no more than six weeks must have elapsed from the last day of induction therapy (the last day of radiation)
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have undergone restaging tests according to the study calendar and determined to have no evidence of disease progression
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have a serum creatinine =< (IULN) AND measured of calculated creatinine clearance >= 60 cc/min using the Cockroft-Gault formula
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Absolute neutrophil count >= 1,500 mcl
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Platelets >= 100,000/mcl
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Hemoglobin >= 9.0 g/dl
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Total bilirubin =< IULN
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: SGOT (AST) or SGPT (ALT) =< 2.5 x IULN
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have Zubrod performance status 0-1
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Arm I (RT, veliparib, carboplatin, paclitaxel)
Patients undergo 3D-CRT and receive veliparib, carboplatin, and paclitaxel as in Phase I induction and consolidation therapy. |
Given IV
Другие имена:
Given IV
Другие имена:
Correlative studies Given PO
Другие имена:
Undergo 3D-conformal RT
Другие имена:
|
|
Активный компаратор: Arm II (3D-CRT, placebo, carboplatin, paclitaxel)
Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days 1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of chemotherapy and radiation therapy, patients receive placebo on days 1-7 and carboplatin and paclitaxel as in Phase I. |
Given IV
Другие имена:
Given IV
Другие имена:
Correlative studies Given PO Undergo 3D-conformal RT
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Maximum Tolerated Dose of Veliparib When Given Concurrently With Standard Carboplatin/Paclitaxel and Radiotherapy, Determined According to Incidence of Dose Limiting Toxicity (DLT) (Phase I)
Временное ограничение: 9 weeks
|
DLTs will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. DLTs must be attributable (probably, possibly, definitely related) to the study regimen and only occur during RT or 2 weeks after completing RT. DLTs are defined as:
|
9 weeks
|
|
Progression-free Survival of Patients Treated With Chemoradiotherapy Plus Veliparib (Phase II)
Временное ограничение: The time from randomization to progression or death due to any cause, assessed up to 5 years
|
Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause. Participants last known to be alive are censored at date of last contact. Assessed by Response Evaluation Criteria in Solid Tumors, RECIST 1.1 |
The time from randomization to progression or death due to any cause, assessed up to 5 years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Overall Survival (Phase II)
Временное ограничение: Up to 5 years
|
From date of registration to date of death due to any cause. Participants last known to be alive are censored at date of last contact. |
Up to 5 years
|
|
Objective Response Rate (Phase II)
Временное ограничение: Up to 5 years
|
ORR is defined as the percentage of participants with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 |
Up to 5 years
|
|
Incidence of Serious (>= Grade 3) Adverse Events as Measured by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Phase II)
Временное ограничение: Duration of treatment and follow up until death or 5 years post registration
|
Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. |
Duration of treatment and follow up until death or 5 years post registration
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Athanassios (Ethan) Argiris, SWOG Cancer Research Network
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оцененный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Новообразования по локализации
- Новообразования
- Новообразования по гистологическому типу
- Новообразования железистые и эпителиальные
- Аденокарцинома
- Новообразования дыхательных путей
- Грудные новообразования
- Новообразования легких
- Карцинома
- Аденокарцинома легкого
- Аденокарцинома, бронхиоло-альвеолярная
- Органические химические вещества
- Терапия
- Углеводороды
- Циклопарафины
- Углеводороды, алициклический
- Углеводороды, циклические
- Терпена
- Координационные комплексы
- Таксииды
- Циклодеканы
- Diterpenes
- Экономика здравоохранения и организации
- Лучевая терапия
- Лучевая терапия, компьютерная помощь
- Экономика
- Карбоплатин
- Паклитаксел
- велипариб
- Лучевая терапия, конформная
- Налоги
Другие идентификационные номера исследования
- NCI-2011-02592
- U10CA032102 (Грант/контракт NIH США)
- U10CA180888 (Грант/контракт NIH США)
- N01CM62209 (Грант/контракт NIH США)
- 8811 (Другой идентификатор: CTEP)
- NCI-2011-02592 (Идентификатор реестра: CTRP (Clinical Trial Reporting Program))
- CHNMC-PHII-111
- CDR0000701003
- PHII-111
- S1206
- 8811 (Другой идентификатор: SWOG)
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .